On March 10, 2024, European Free Trade Association countries (Iceland, Liechtenstein, Norway and Switzerland) and India announced signing of the free trade agreement which was being negotiated since 2006. While some provisions undermining generic competition were removed, MSF remains wary of clauses in supplementary documents related to intellectual property. Our analysis reveals the clauses that can dilute the use of public health safeguards under the Indian Patent Law, which have ensured access to affordable medicines for India and other developing countries.
